A Oneindia Venture
Click it and Unblock the Notifications
Senores Pharmaceuticals Ltd. IPO
Senores Pharmaceuticals Ltd., established in 2017, operates in the Pharmaceuticals sector. The company's IPO opened on December 20, 2024 and closed on December 24, 2024, with an issue price of ₹391. ... Read more
IPO Timeline
-
20 Dec 2024Bidding Starts
-
24 Dec 2024Bidding Ends
-
26 Dec 2024Allotment Finalization
-
30 Dec 2024Listing
About Senores Pharmaceuticals Ltd.
We are a global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms. Our Regulated Markets business is primarily ... Read more
Senores Pharmaceuticals Ltd. IPO Reservation
| Investors Category | Shares Offered |
|---|---|
| Anchor Investors | 66,65,726 (44.77%) |
| Employee Reserved | 75,000 (0.5%) |
| Non Institutional Investors | 22,21,909 (14.92%) |
| Qualified Institutional Buyers (QIBs) | 44,43,817 (29.85%) |
| Retail Individual Investors (RIIs) | 14,81,272 (9.95%) |
Senores Pharmaceuticals Ltd. Financial Information
| Year End | Revenue | PAT | Reserves & Surplus |
|---|---|---|---|
| 31 Mar 2024 | 40.85 Cr | 81.40 Lakh | 137.61 Cr |
| 31 Mar 2023 | 19.17 Cr | 1.20 Cr | 29.11 Cr |
| 31 Mar 2022 | 16.89 Cr | 29.30 Lakh | 25.01 Cr |
Senores Pharmaceuticals Ltd. Background
-
2021Incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US.
Entered into a new segment of API with acquisition of Ratnagene Lifescience Private Limited.
-
2022Started the domestic business with a launch of the critical care injectables
-
2023Acquired majority stake in Havix., making it a Subsidiary of our Company
Consolidated our presence in emerging markets by acquiring shares in Ratnatris Pharmaceuticals Private Limited, making a Subsidiary of our Company.
-
2024Launched first CMO product in the US with Jubilant Cadista
1. Investment in one of our Subsidiaries, Havix, to fund capital expenditure requirements, to fund capital expenditure requirements for setting up a manufacturing facility for the production of sterile injections in our Atlanta Facility
2. Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company
3. Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiary
4. Funding the working capital requirements of our Company
5. Investment in our Subsidiaries, namely, SPI and Ratnatris to fund their working capital requirements
6. Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes
| Pricing Details | BSE | NSE |
|---|---|---|
| Issue Price | ₹ 391.00 | ₹ 391.00 |
| Open | ₹ 593.70 | ₹ 600.00 |
| Low | ₹ 538.85 | ₹ 538.85 |
| High | ₹ 609.00 | ₹ 609.65 |
| Last Trade | ₹ 557.80 | ₹ 557.05 |
1. Swapnil Jatinbhai Shah
2. Ashokkumar Vijaysinh Barot
As per the F&S Report, the US pharmaceutical market increased from USD 589.0 billion in CY 2021 to USD 711.0 billion in CY 2023. The US CDMO market grew from USD 36.3 billion in CY 2021 to USD 44.7 billion in CY 2023. The Emerging pharmaceutical market rose from USD 354.3 billion in CY 2021 ... Read more
FAQs
When does Senores Pharmaceuticals Ltd. IPO opens and closes?
What is the size of Senores Pharmaceuticals Ltd. IPO?
What is the price range of Senores Pharmaceuticals Ltd. IPO?
What is the minimum investment and lot size required for the Senores Pharmaceuticals Ltd. IPO?
When is Senores Pharmaceuticals Ltd. IPO listing date?
What is the objective of Senores Pharmaceuticals Ltd. IPO?
2. Re-payment/pre-payment, in full or in part, of certain borrowings availed by our Company
3. Investment in our Subsidiary, namely, Havix, for re- payment/pre-payment in full or in part, of certain borrowings availed by such Subsidiary
4. Funding the working capital requirements of our Company
5. Investment in our Subsidiaries, namely, SPI and Ratnatris to fund their working capital requirements
6. Funding inorganic growth through acquisition and other strategic initiatives and general corporate purposes
Disclaimer: This is 3rd Party content/feed, viewers are requested to use their discretion and conduct proper diligence before investing, GoodReturns does not take any liability on the genuineness and correctness of the information in this article
-
Upcoming IPO: Senores Pharma To Open Rs 582 Crore Public Issue For Subscription Tomorrow; Check Details -
CMPDI IPO Lists at 7% Discount on NSE, BSE; Weak Demand Keeps Stock Under Pressure Despite Mild Recovery -
CMPDI IPO Allotment Today: Did You Get Shares? Check Status Now on KFin, NSE, BSE -
Powerica IPO Off to Slow Start: GMP Up 1.2%, But Subscription Stuck at 0.01x; Is It Worth Applying? -
CMPDI IPO Underwhelms: Day 2 Subscription At 10%, No Movement In GMP; What's Behind The Weak Demand? -
Upcoming IPOs Next Week: CMPDI, Sai Parenteral, Powerica, Vivid Electromech, More | Check Full List -
XED Executive Development IPO: GIFT City Sees First IPO; Price Band, Issue Size | All You Need to Know -
Skyways Air IPO vs CMPDI IPO: Full Comparison of Price Band, GMP, Lot Size, Listing & Allotment Date -
Coal India's CMPDI IPO GMP Shows 11% Listing Gain Potential; Everything You Need To Know -
Big Change in IPO Rules: Govt Updates Minimum Public Offer Norms for for IPO-bound Firms -
Raajmarg Infra Investment Trust InvIT IPO Closed with 1323% Subscription on Day 3; GMP Remains Flat
-
Block for 8 hours
-
Block for 12 hours
-
Block for 24 hours
-
Don't block
Sign in with Google- Male
- Female
- Others
- Under 18
- 18 to 25
- 26 to 35
- 36 to 45
- 45 to 55
- 55+